Eculizumab for atypical hemolytic-uremic syndrome in India: First report from India and the challenges faced
Much progress has been made in understanding the pathophysiology and treatment of atypical hemolytic uremic syndrome (aHUS). Plasma therapy is the mainstay of treatment for aHUS. The availability of the first effective anti-complement therapeutic agent, eculizumab, has dramatically changed the outlo...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
| Series: | Indian Journal of Nephrology |
| Subjects: | |
| Online Access: | http://www.indianjnephrol.org/article.asp?issn=0971-4065;year=2017;volume=27;issue=1;spage=58;epage=61;aulast=Sethi |